Skip Navigation LinksHome > November 2009 - Volume 31 - Issue 11 > Intrathecal Vincristine: 3 Fatal Cases and a Review of the L...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3181b83fba
Original Articles

Intrathecal Vincristine: 3 Fatal Cases and a Review of the Literature

Hennipman, Bernadette MBBS*; de Vries, Esther MD, PhD; Bökkerink, Jos P. M. MD, PhD‡ §; Ball, Lynn M. MD, FRCP, FRCPath, FRCPCH; Veerman, Anjo J. P. MD, PhD* §

Collapse Box

Abstract

We report 3 cases of accidental intrathecal vincristine administration. All 3 patients died between 8 and 18 days after the incident because of decerebration. In the literature, we found 41 cases of accidental intrathecal injection of vincristine. These reports represent only a fraction of the existing problem. New in our report is the fact that the first 2 cases were attributed to viral infection, only after the detection of high levels of vincristine in the cerebrospinal fluid was the real cause of death ascertained. The third case occurred during the implementation of rules by the Dutch Childhood Oncology Group on how to handle intrathecal triple therapy; and despite sequential safety measures, the accident still occurred. In the Netherlands no more accidents of this nature have occurred in children after the introduction of a quadruple syringe system 8 years ago. In our opinion the best fail-safe solution would be the development of a unique connection that is incompatible with a standard Luer syringe.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.